Mark Foote Dalton

Mark Foote Dalton

Director/Board Member at Tudor Riverbend Crossing Partners LP

73 year
Finance
Consumer Services
Commercial Services

Profile

Mark Foote Dalton is currently a Director at The Buoniconti Fund to Cure Paralysis, Inc. and Tudor Riverbend Crossing Partners LP.
Previously, he was the Co-Chairman & Chief Executive Officer at Tudor Investment Corp., an Independent Director at Progenics Pharmaceuticals, Inc., a Principal at Sullivan & Cromwell LLP, and the Chief Financial Officer at Kidder, Peabody & Co., Inc. He received his undergraduate degree from Denison University in 1972 and his graduate degree from Vanderbilt Law School in 1975.

Mark Foote Dalton active positions

CompaniesPositionStart
Director/Board Member -
Director/Board Member -
All active positions of Mark Foote Dalton

Former positions of Mark Foote Dalton

CompaniesPositionEnd
PROGENICS PHARMACEUTICALS, INC. Director/Board Member 2012-06-12
Corporate Officer/Principal -
Director of Finance/CFO 1987-12-31
Chief Executive Officer -
See the detail of Mark Foote Dalton's experience

Training of Mark Foote Dalton

Denison University Undergraduate Degree
Vanderbilt Law School Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark Foote Dalton's experience

Connections

96

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies6

Finance

Health Technology

Finance

Commercial Services

Finance

Commercial Services

See company connections
  1. Stock Market
  2. Insiders
  3. Mark Foote Dalton
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW